Answers are grounded in this paper and cite their sources.
New dosimetry system measures doses accurately in Ru-106 plaque brachytherapy, suggesting improved quality assurance.
The PFD enabled accurate and high-resolution dose measurements on the curved surfaces of Ru-106 plaques. Both planar and CAX measurements demonstrated strong agreement with manufacturer-certified reference data across all plaque types. This system offers a practical and reproducible solution for commissioning and QA in Ru-106 plaque brachytherapy, supporting its clinical integration for choroidal melanoma treatment.
No takes yet. Share an insight, caveat, or question.
Cho et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: